Home › Trial NCT03735875
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- Trial IDNCT03735875
- StatusTerminated
- PhasePhase 1/2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment8
- Start date2019-01-25
- ConditionsAcute Myeloid Leukemia With FLT3/ITD Mutation · Recurrent Acute Myeloid Leukemia · Refractory Acute Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.